Uniqure NV (QURE) Stock Analysis
Verdict: AVOID
AMT-130 BLA submission offers major upside, but history of FDA data friction, $178M annual cash burn, and continuous equity dilution cap safety.
Investment score: 38/100
Analysis as of
Is Uniqure NV stock worth reviewing? AI model thesis
The AI model classifies QURE as an AVOID at $24.51 following a -37.33% daily plunge and insider sales. While the BLA submission for AMT-130 in Huntington's disease and $810.33M in liquid reserves provide mid-term pipeline optionality, historical FDA friction, ongoing shareholder litigation, and TTM operating margins of -1089.1% represent elevated speculative risk.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 15/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Uniqure NV opportunities and risks
What speaks for QURE
- AMT-130 BLA filing submission positions company for potential FDA priority review.
What speaks against QURE
- Regulatory friction and scrutiny regarding AMT-130 clinical data integrity.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| QURE | n/a | 91.1x | n/a | 22.8% | -1350.7% | -9.5% |
| NAMS | n/a | 390.9x | n/a | 92.1% | -3644.2% | -5.2% |
| PRQR | n/a | 8.2x | n/a | 92.3% | -228.3% | -32.9% |
| Peer median | n/a | 199.6x | n/a | 92.2% | -1936.2% | -19.0% |
Frequently asked questions about Uniqure NV (QURE)
Is QURE stock a good investment?
The cached TradeMates AI model rates Uniqure NV as AVOID with an investment score of 38/100. The AI model classifies QURE as an AVOID at $24.51 following a -37.33% daily plunge and insider sales. While the BLA submission for AMT-130 in Huntington's disease and $810.33M in liquid reserves provide mid-term pipeline optionality, historical FDA friction, ongoing shareholder litigation, and TTM operating margins of -1089.1% represent elevated speculative risk. This is algorithmic model output, not personal investment advice.
Is QURE stock a buy?
The TradeMates model verdict for QURE is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.